NLRP3 is dispensable for d-galactosamine/lipopolysaccharide-induced acute liver failure

Wen Zhang,Shou-Song Tao,Ting Wang,Ya-Ting Li,Hui Chen,Yi-Qun Zhan,Miao Yu,Chang-Hui Ge,Chang-Yan Li,Guang-Ming Ren,Rong-Hua Yin,Xiao-Ming Yang

DOI: https://doi.org/10.1016/j.bbrc.2020.10.003

IF: 3.1

2020-12-01

Biochemical and Biophysical Research Communications

Abstract:<p>The nucleotide-binding domain and leucine-rich repeat-containing family pyrin domain containing 3 (NLRP3) inflammasome is involved in various acute and chronic liver diseases, however, it is not clear whether NLRP3 contributes to <span class="small-caps">d</span>-Galactosamine (D-GalN) plus lipopolysaccharide (LPS)-induced acute liver failure (ALF). This study aims to investigate the role of NLRP3 inflammasome in D-GalN/LPS-induced fatal hepatitis. We found that <em>Nlrp3</em>^−/− and WT mice showed similar mortality against a lethal dose of D-GalN/LPS treatment. Serum ALT and AST levels, as well as liver necrosis area and hepatocyte apoptosis, were not significantly different between <em>Nlrp3</em>^−/− and WT mice at 6 h after D-GalN/LPS injection. Moreover, the numbers of intrahepatic F4/80⁺ cells and Ly6G⁺ cells were comparable in two genotype mice following D-GalN/LPS treatment. Besides, <em>Nlrp3</em>^−/− mice had reduced IL-1β levels but similar TNF-α, IL-6, and MCP-1 levels compared with WT mice upon D-GalN/LPS administration. Our findings revealed that NLRP3 ablation does not protect mice from D-GalN/LPS-induced fatal hepatitis and has a marginal effect on intrahepatic inflammatory response upon D-GalN/LPS treatment. This suggests that NLRP3 inflammasome does not appear to be a major contributor to D-GalN/LPS-induced ALF.</p>

biochemistry & molecular biology,biophysics